Aaptamine has potent cytotoxicity that may be explained by its ability to intercalate DNA. Aaptamine was evaluated for its ability to bind to DNA to validate DNA binding as the primary mechanism of cytotoxicity. Based on UV-vis absorbance titration data, the K obs for aaptamine was 4.0 (±0.2) × 10 3 which was essentially equivalent to the known DNA intercalator N-[2-(diethylamino)ethyl]-9-aminoacridine-4-carboxamide. Semi-synthetic core modifications were performed to improve the general structural diversity of known aaptamine analogs and vary its absorption characteristics. Overall, 26 aaptamine derivatives were synthesized which consisted of a simple homologous range of mono and di-N-alkylations as well as some 9-O-sulfonylation and bis-O-isoaaptamine dimer products. Each product was evaluated for activity in a variety of whole cell and viral assays including a unique solid tumor disk diffusion assay. Details of aaptamine's DNA-binding activity and its derivatives' whole cell and viral assay results are discussed.
The proposed biogenesis of aaptamine suggests a possible Pictet-Spengler type condensation commonly attributed to many other natural alkaloids (16) . Likewise, three common pharmacophores can be recognized in the aaptamine scaffold: isoquinoline, the largest class of alkaloids isolated from medicinal plants; dopamine, a compound affecting the central nervous system and behavior; and finally, quinoline, known primarily for its anti-malarial properties.
Aaptamine's potential for drug development is further evidenced by the actual results of a highly diverse group of molecular targets already evaluated. In addition to antiviral (5 , 17) and anticancer (4 , 6 , 18) activities, the aaptamines have a strong in vitro radical scavenging capacity (19) and have been shown to block α-adrenoceptor action (1) as well as inhibit α-1,3-glucanase (20) and monoamine oxidase (21) . Still, compounds which are active against a variety of targets are certain to encounter problems with indiscriminant toxicities. It is important to recognize toxicity as a hurdle for the development of aaptamine as a useful drug but not let it prohibit the evaluation of its derivatives for therapeutic potential. The 'privileged structures' approach (22) is dependent on exploiting a scaffold's common a A variety of species of Aaptos have been named in the production of aaptamine above, including sponges identified as Aaptos aaptos (1 , 2 , 4) or simply Aaptos sp. (5) . Kelly-Borges and Bergquist (33) indicated that it was highly unlikely that Aaptos aaptos (Schmidt, 1864), originally described from Lagoste, Algeria, was 'cosmopolitan' as much of the earlier literature suggested, but that specimens from locations such as Okinawa (1 , 2) might be closer to Aaptos niger Hoshino. Similarly, the specimens described as 'Aaptos sp.' (5) from Brazil, is most likely either A. nigra Lévi (blackish dark orange to gold with a deep yellow interior), or A. chromis de Laubenfels, 1954 (bright green with a yellow interior). b A re-examination of the specimen in Calcul et al. (2003) has confirmed that the sponge is most closely related to the widely spread Indo-Pacific sponge Neopetrosia exigua (Kirkpatrick, 1900) (Order Haplosclerida: Family Petrosiidae), formerly known as Xestospongia exigua. The genus Neopetrosia is clearly phylogenetically distinct from the genus Aaptos (Order Hadromerida: Family mechanism of drug-target interaction for multiple targets. In a similar fashion, a key for the development of the aaptamine scaffold is the identification of its common mechanism of drug-target interaction.
Although it is difficult to determine if broad-spectrum DNA-interaction is a compound's definitive mechanism of cytotoxicity, it is clear that DNA interaction has a measurable influence on the mechanism. Small molecules that bind to DNA do not necessarily interact in the same way, in fact, there are several modes by which a ligand can bind and affect the structure and function of this substrate (23) . Of these modes, intercalation is most prevalent with planar polycyclic aromatic systems like the aaptamines which insert between adjacent base-pairs of intact DNA, depending primarily on p-bond interactions and sometimes stacking several molecules together in the same area between base pairs. The quinoline portion found in aaptamine's tri-cyclic core has already been the focus of SAR studies with derivatives of acridine (24), a structure that resembles aaptamine and is a well studied anti-cancer pharmacophore that intercalates DNA. The observed DNA binding activity of aaptamine may serve to explain some aspects of the compound's mechanism of activity against whole cell and viral pathogens.
Considering the high availability of the natural material and the remarkably broad activity displayed, this heterocyclic small molecule has excellent potential as a scaffold from which numerous derivatives can be made in an attempt to improve selectivity and pharmacokinetics.
Based on the synthetic work already published by Shen et al. (18) , Hibino et al . ( 12) , Pettit et al . ( 25 , 26) and Gul et al . ( 27) a preliminary SAR has been developed for the aaptamine scaffold in regard to cytotoxicity, antiviral and antimicrobial activity. Table 1 summarizes what has been learned of this relationship from the synthetic and natural derivatives of aaptamine.
Utilizing the information from this SAR, a semi-synthetic series of N-alkyl aaptamine derivatives was produced to complement previously published N-alkylation efforts that improved activity, and to investigate the effects of increasing the lipophilic character of the pharmacophore. In addition, it was proposed that selective demethylation of the C-9 hydroxyl would significantly increase the potency of the first generation N-alkyl derivatives.
Our speculation was based on the evidence wherein 2 consistently demonstrated higher potency than 1 in a variety of biological assays; likewise the selective demethylation of the aaptamine derivatives would produce isoaaptamine analogs with higher potency. Two smaller groups of analogs were specifically produced to investigate the effect of dimerization on biological activity and the pro-drug behavior of sulfonyl esters relative to those previously studied.
Methods and Materials

Sponge collection and taxonomy
The sponge was collected from reef slopes at about 20 m depth, from Derawan Island and Manado Bay, Indonesia. In life the sponge forms a dense, tough, tuber-like mass, with a relatively smooth surface that may be pitted and feels like sandpaper to the touch. In life the sponge is dark orange, the interior deep yellow, the sponge oxidizes to a deep dark gold color, rendering the preservative fluorescent dark gold. The skeleton consists of large strongyloxeas in three size categories, disposed radially in the ectosome and throughout the choanosome. The sponge is Aaptos nigra Lévi, 1961 (Demospongiae: Hadromerida: Suberitidae), first described from Vietnam. A voucher specimen has been deposited in the Natural History Museum, London (BMNH 2005.2.16.1).
Isolation of aaptamines
The sponge Aaptos nigra (30 kg, wet) was extracted with 95% EtOH. Aaptamine (200 g, 1.9%) and isoaaptamine (230 g, yield 2.2%) were purified from the crude extract by VLC and MPLC using normal phase conditions analogous to several previously published procedures. As needed, additional purification was performed using reverse phase HPLC, affording smaller amounts of 1 and 2 of high purity.
Synthesis
General-With the exception of the demethylation chemistry, all reactions were performed under a nitrogen atmosphere. Reaction media were either utilized from anhydrous solvent containers obtained from Sigma-Aldrich Co. or dried through typical laboratory protocols. All reagents were purchased from Sigma-Aldrich as well. Parallel synthesis was achieved with the Firstmate ® 12 unit parallel synthesizer (Argonaut Technologies, Inc.). Unless stated otherwise, reaction and purification monitoring was done using thin layer chromatography with silica gel 60 F254 aluminum-backed sheets (Merck KGaA) and visualized with long wave UV (365 nm). Flash column chromatography was performed with silica gel 60 (particle size 40-63 mm, 230-400 mesh, Silicycle Inc.). Preparative gel chromatography was performed using Sephadex LH-20 (GE Healthcare Bio-Sciences Corp.). All 1 H and 13 C NMR spectra were acquired on the Bruker DRX 400 MHz Spectrometer using XWinNMR software and an internal solvent calibration. High resolution mass spectra were acquired on the Bruker ESI-micrOTOF in positive mode coupled with an Agilent HPLC. All synthetic procedures are summarized in Scheme 1.
Parallel N-Alkylation-In each reaction tube of the parallel synthesizer, 200 mg (0.88 mmol) of 1 was dissolved in DMF (20 mL) at 0 °C. To the solution, approximately 3 equivalents of KH were added and the mixture was stirred for 10 min after which 1.2 equivalents of the appropriate alkyl iodide was added drop-wise. The reaction was stirred for an additional hour and then allowed to warm to room temperature. While at room temperature, the reaction was monitored by TLC to insure complete conversion of the starting material which occurred usually after 18-24 h. Workup consisted of aqueous extraction with CHCl 3 , a brine wash and drying over Na 2 SO 4 before evaporation under reduced pressure. Final purification was completed on a silica flash column using 5% MeOH in ammonia saturated DCM which in most cases provided two regioisomers that required multiple repetitions of the same chromatography step to purify. Scale up of some selected derivatives was required for further study.
Sulfonylation-In a round bottom flask, 200 mg (0.88 mmol) of 2 was suspended in DCM (15 mL). To the solution, approximately two equivalents of Et 3 N was added and allowed to stir for ten minutes at room temperature. The mixture was cooled to 0 °C and a DCM solution (5 mL) containing 1.2 equivalents of the appropriate sulfonyl chloride were added drop-wise over ten minutes. The reaction was stirred for an additional hour and then allowed to warm to room temperature. The solvent was removed under reduced pressure and purification was completed on a flash column with 10% MeOH in DCM.
Dimerization-In a round bottom flask fitted with a condenser, 200 mg (0.88 mmol) of 2 and cesium carbonate was suspended in acetone (40 mL). To the solution, 0.5 equivalents of the appropriate dibromoalkane were added and the mixture was refluxed while stirring to thoroughly maintain the suspension. The product precipitated from acetone and the reaction was complete when the starting compound was not detected in the solvent using mass spectrometry. Purification consisted of filtering the product from acetone, reconstituting the product in MeOH and purification by LH20 in MeOH.
Demethylation-Two methods were used for the synthesis of the demethylated aaptamines. Method A utilized BBr 3 to produce 8,9-demethylaaptamine (30) . Method B is previously described (26) , and utilized hydrobromic acid with controlled heating to selectively demethylate the 9-O methyl function of aaptamine.
For method A, 200 mg (0.88 mmol) of 1 was suspended in DCM (25 mL) in a round bottom flask at 0 °C. To the suspension, four equivalents of BBr 3 (1.0M in DCM) was added over 10 min. The mixture was allowed to warm to room temperature and stirred for 3 h. The solid material was filtered from the reaction and washed with DCM to give a green precipitate which was purified by LH20 in MeOH.
For method B, 200 mg of 1N,4N-didodecylaaptamine (21) (0.35 mmol) was added to a round bottom flask. The material was suspended with 3-4 mL 48% HBr and heated at 115 °C for approximately 30 min with stirring. The reaction was quenched with 1-2 mL water and extracted with CHCl 3 . The organic layer was washed with brine solution and dried over Na 2 SO 4 . Usual column chromatography (10% MeOH in DCM) afforded 165.6 mg of compound 30.
8,9-Dimethoxy-1-methyl-1H-benzo[de][1,6]naphthyridine (1N-methylaaptamine) (5):
Yellow amorphous solid. Yield 21%. 1 
8,9-Dimethoxy-4-methyl-4H-benzo[de][1,6]naphthyridine (4N-methylaaptamine) (6):
Yellow amorphous solid. Yield 34%. HR-ESI-MS m/z, H 1 and C 13 -NMR δ values match those previously reported (26).
1-Ethyl-8,9-dimethoxy-1H-benzo[de][1,6]naphthyridine (1N-ethylaaptamine) (7):
Yellow amorphous solid. Yield 29%. 1 
4-Ethyl-8,9-dimethoxy-4H-benzo[de][1,6]naphthyridine (4N-ethylaaptamine) (8):
Yellow amorphous solid. Yield 41%. 1 
8,9-Dimethoxy-1-propyl-1H-benzo[de][1,6]naphthyridine (1N-propylaaptamine) (9):
Yellow amorphous solid. Yield 30%. 1 
8,9-Dimethoxy-4-nonyl-4H-benzo[de][1,6]naphthyridine (4N-nonylaaptamine) (19):
Yellow amorphous solid. Yield 45%. 1 
1,4-Didodecyl-8,9-dimethoxy-4H-benzo[de][1,6]naphthyridin-1-ium Iodide (1N,4Ndidodecylaaptamine as iodide salt) (21): Yellow amorphous solid. Yield
8-Methoxy-1-methyl-1H-benzo[de][1,6]naphthyridin-9-yl propane-1-sulfonate (9-Opropylsulfonylisoaaptamine) (24):
Yellow amorphous solid. Yield 80%. 1 
8-Methoxy-1-methyl-1H-benzo[de][1,6]naphthyridin-9-yl phenylmethane-sulfonate (9-O-phenylsulfonylisoaaptamine) (26):
Yellow amorphous solid. Yield 62%. 1 
1,6-Bis-(8-methoxy-1-methyl-1H-benzo[de][1,6]naphthyridin-9-yloxy)-hexane (1,6bisisoaaptamine hexane) (27):
Yellow amorphous solid. Yield 89%. 1 Bis-(8-methoxy-1-methyl-1H-benzo[de][1,6]naphthyridin-9-yloxy)-nonane (1,9 DNA Binding Assay-The interaction of aaptamine with calf thymus DNA was examined by UV-vis spectrophotometry following a previously published procedure, standardized with the acridine derivative AAS (24) .
1,9-
Disk Diffusion Soft-Agar Colony Formation Assay for Cytotoxicity-
The method used in the determination of cytotoxicity was a slight variant of a previously published procedure (28) . A disk diffusion assay was used to determine the compounds selectivity for cancer cell growth inhibition. Two murine neoplasms, leukemia (L1210) and colon (Colon38), three human neoplasms, colon (H116), lung (H125) and leukemia (CCRF-CEM) along with one normal cell type (hematopoietic progenitor) were utilized. This assay focuses on a compounds ability to preferentially inhibit solid tumor cells in order to identify agents with mechanisms of action different from standard anticancer leads identified through typical in vitro screening protocols. One novelty of the assay lies in the fact that diffusion characteristics do not directly influence the observations of each individual compound's selectivity among the neoplasms. Positive results can take several forms as selectivity can be defined between either the murine or human solid tumor cells compared to either the normal or leukemia cells. Compounds are dissolved in DMSO and 15 μL are applied to a 6.5 mm Baxter filter disk. The disk is dried overnight and a then placed near the edge of the Petri dish containing the culture and incubated for 7-10 days. Values are measured in zone units from the edge of the test disk in which 200 zone units is arbitrarily taken as 6.5 mm (the diameter of the disk). Approximately 1 mg of each compound was diluted in 0.25 mL DMSO. Solutions are diluted further (e.g. 1/4 and 1/16) if the initial test yields a zone of 750 units or more.
Results and Discussion
In all, twenty seven derivatives were synthesized for biological evaluation; Figure 2 shows the four groups of derivatives produced through semi-synthesis along with their calculated Log D values c demonstrating the range of increasing lipophilic or hydrophilic character in comparison Log D values for compounds 1 and 2 at 1.51 and 1.57 respectively. The isoaaptamine dimers 27 and 28 represent a preliminary attempt to improve selectivity by providing two possible sites of compound interaction with the target. The fully demethylated compound 29 has been isolated (29) and synthesized (26) previously, but has not been evaluated for its anti-viral activity. Selectively demethylated derivative 30 represents the first of the proposed second generation derivatives produced from the dialkylated compound 21. Table 2 summarizes the activity against microbial and AIDS related opportunistic infections. Overall, the data show that several of the N-alkyl analogs have potency against bacteria and are moderately active as antifungal agents. Of particular interest is the significant activity of some of the analogs against the methicillin resistant strain of Staphylococcus aureus (MRSa). None of the alkylation products having five or less carbon units in their N-alkyl chains were active. The predicted Log D values for the completely inactive N-alkyl compounds ranged from 2.21 to 3.75, and the Log D for the most active against MRSa was 6.01. The activity against MRSa peaks with 1N-dodecyl (20) and then the activity diminished for derivatives 21 and 22 which have higher Log D values. It is therefore reasonable that in this homologous series, the optimal chain length should produce a Log D between 3.75 and 7.09 to be effective against MRSa.
Activity against the chloroquine sensitive (D6) and resistant (W2) Plasmodium falciparum strains was improved (Table 3) , and similar to the anti-microbial activity, notable improvement occurs with derivatives having more than five carbon units in the alkyl chain. However, there is distinct improvement in the activity seen with compound 30.
Demethylation of the C-9 methoxy of compound 21 gives over a ten fold increase in activity against the resistant strain; this supports our observations from the previous SAR studies that protection of the C-9 hydroxyl will generally decrease potency.
Although this is the first report of aaptamine derivatives having activity against Mycobacterium tuberculosis, the in vitro results for all derivatives ranged from moderate to inactive. In several cases though, the activity paralleled that of the less virulent Mycobacterium intracellulare (Table 2) supporting its value as a guide for the development of anti-tuberculosis analogs. Table 4 lists the activity of the aaptamine derivatives against HIV-1 in human peripheral blood mononuclear (PBM) cells. Cytotoxicity for PBM, T-lymphoblastoid (CEM) and African green monkey kidney (Vero) cell lines were also measured to determine the therapeutic selectivity of active derivatives. Although several of the derivatives have significantly improved activity against HIV-1, cytotoxicity for the majority of the compounds was high in comparison to the control. Table 5 shows the observed cytotoxicity for aaptamine semi-synthetic derivatives in the disk diffusion soft-agar colony formation assay. The disk diffusion assay provided a unique analysis of relative selectivity. Compounds 11 and 14-17 showed good potency and selectivity against murine colon tumor cells versus leukemia and normal cells. In addition to this assessment, N-alkyl derivatives 17 and 20, isoaaptamine dimer 2 and the demethylated derivative 30 were chosen for assessment in the 60-cell cytotoxicity panel at the National Cancer Institute. Their evaluation in this in vitro panel showed good potency but low selectivity and corresponds to the data shown for the same derivatives in the disk diffusion assay.
Aaptamine was evaluated for its ability to bind to DNA by UV-vis spectroscopy. Figure 3 shows that in addition to the pronounced decrease in absorbance intensity (hypochromicity) of aaptamine upon DNA binding, a bathochromic (red) shift in the λ max of aaptamine was also observed, with λ max increasing from 381 nm for the free ligand species to 391 nm as the ligand becomes bound to the DNA. This 10 nm bathochromic shift in absorbance is indicative of the formation of an intercalative complex. The inset shows the absorbance at 381 nm as a function of log [DNA]; the solid line represents the nonlinear least-squares fit of the binding isotherm model (30) to the titration data and provides an estimate of the intrinsic binding constant K obs . The interaction of aaptamine with calf thymus DNA was characterized by a binding affinity of 4.0 (±0.2) × 10 3 M-1 (base pairs) a relatively weak binding affinity, but comparable to that reported for AAS, a known cytotoxin and DNA intercalator (24) . 12 This DNA binding data, the published cytotoxicity and anti-viral activity together suggest that aaptamine utilizes DNA intercalation in its mechanism of action for these particular targets. Some analogs presented herein with improved anti-tumor, antimicrobial and anti-malarial activity could also utilize this mechanism.
Conclusions and Future Directions
The limit of chemical diversity in the marine environment is still undetermined and will continue to grow with ongoing improvements in the technology associated with collection and isolation of natural products. However, it has been demonstrated that a large number of bioactive secondary metabolites become clinical candidates through semi-synthetic optimization of their original structure (31) . The simplicity of aaptamine's core structure, the potential for orally bioavailable analogs and its ability to intercalate DNA provide a unique opportunity for drug discovery. Aaptamine could be an ideal candidate for an emerging technique such as fragment-based drug design, which utilizes molecules with relatively non-specific target interactions (32) . Our studies of the currently available structure activity relationship and the knowledge gained through modifications and subsequent biological assessments contribute to the development of this pharmacophore for cancer, HIV-1 and infectious disease. Further modifications are undoubtedly necessary due to the observed cytotoxicity, not to mention improved potency against the other anti-viral and whole cell targets shown. Although the cyototoxicity appears to track activity in other whole cell assays, this is a typical result for compounds that interact with DNA. However, the intercalative function of aaptamine can become a benefit rather than a liability when used in combination with additional functionality that provides better selectivity. Table 1 Summary of reported relative structure activity relationships for aaptamine based on general improvements of either potency or selectivity Table 2 In vitro activity of aaptamine and derivatives (1, 2, 5-30) against microbial and AIDS related opportunistic infections 
